1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Cardiometabolic Syndrome in 2 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Madec, S | 1 |
| Rossi, C | 1 |
| Chiarugi, M | 1 |
| Santini, E | 1 |
| Salvati, A | 1 |
| Ferrannini, E | 1 |
| Solini, A | 1 |
| Schinzari, F | 1 |
| Tesauro, M | 1 |
| Rovella, V | 1 |
| Di Daniele, N | 1 |
| Gentileschi, P | 1 |
| Mores, N | 1 |
| Campia, U | 1 |
| Cardillo, C | 1 |
2 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Adipocyte P2X7 receptors expression: a role in modulating inflammatory response in subjects with metabolic syndrome?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine Triphosphate; Adipocytes; Aged; Blotting, W | 2011 |
Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Antioxidants; Drug Resistance; Endothelium, Va | 2012 |